Could a simple Vitamin-Like injection slash anemia drug use in kidney dialysis?
NCT ID NCT07160452
First seen Sep 30, 2025 · Last updated Jun 21, 2026 · Updated 31 times
Summary
This study tests whether adding levocarnitine injections to standard care can reduce the amount of anemia medication needed by people on kidney dialysis. About 94 adults on long-term dialysis will receive either levocarnitine after each session or usual care alone for 6 months. The goal is to see if levocarnitine helps maintain healthy red blood cell levels with lower drug doses, which could cut costs and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Levocarnitine (a form of carnitine) given as an injection after dialysis
What this could lead to
If it works, this could offer a cost-effective way to manage anemia in dialysis patients by reducing the dose of standard anemia drugs needed.
What could go wrong
This is a small, single-center Phase 4 trial with only 94 participants. The benefit may be modest or not seen at all, and results may not apply to all dialysis patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.